LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

High-End Hematology Analyzers Compared for Overall Equipment Effectiveness

By LabMedica International staff writers
Posted on 29 Apr 2022
Image: The Yumizen H2500 hematology analyzer (Photo courtesy of Horiba)
Image: The Yumizen H2500 hematology analyzer (Photo courtesy of Horiba)

Although the performance of the automated hematology analyzers expressed as turn-around time is one of the important criteria in high-volume testing laboratories to deliver patient quality results on time, it may not be comparable for the analyzers from different companies.

In clinical laboratories with a heavy patient load, the testing quality of the automated hematology analyzers depends on their accuracy, reliability, and performance as well as efficiency. Continuous evaluation of the equipment with the appropriate methods is the key to ensure sustained quality of reporting in clinical laboratories.

Medical Laboratorians at the Christian Medical College (Vellore, India) and their colleagues evaluated and compared the overall equipment effectiveness (OEE), sensitivity, specificity, and efficiency of high-end hematology analyzers. A total of 400 anonymized left over’s K2 EDTA whole blood samples were analyzed for complete blood count (CBC). CBC analysis of all blood samples was performed using the different automated hematology analyzers.

The study was a was a prospective cross-sectional comparative study of four hematology analyzers: Yumizen H2500 (Horiba, Kyoto, Japan), the DxH 800 and DxH 900 (Beckman Coulter, Miami, FL, USA), and the XN-9000 (XN-10) (Sysmex Corporation, Kobe, Japan). The Yumizen H2500 uses the double hydrodynamic sequential system and the impedance method. Both DxH 800 and DxH 900 use impedance, and five light scatter and absorption measurements (volume, conductivity, and scatter [VCS] technology) method. This Sysmex XN-10 uses fluorescence and flow cytometry technology with a semiconductor laser to categorize WBCs. In case of additional fluorescence interference, it uses a recently developed a “parasitic red blood cell” (pRBC) flag to correct WBC counts on the WBC differential scattergram.

The investigators reported that the OEE was good and comparable for all the hematology analyzers except DxH 800 showing an average status. Confusion matrix highlights the difficulty for DxH 800 and DxH 900 to discriminate left shift or blasts with large hyper-segmented neutrophils. The flags triggered by Yumizen H2500 were markedly changed to large hyper-segmented neutrophils. Lymphoblast caused more misperception for XN-9000 (XN-10), as it came out to be atypical lymphocytes, or hypersegmented neutrophils. Although comparable in OEE index to other analyzers, the Yumizen H2500 seems to be more reliable in detecting the abnormal cells as it has high sensitivity, specificity and less turnaround time.

The authors concluded that all four hematology analyzers showed comparable OEE in technical evaluation. However, the Yumizen H2500 analyzer seems to be more reliable in detecting the abnormal cells as it has high sensitivity, specificity and less turnaround time compared to other analyzers. The study was published on April 26, 2022 in the journal Practical Laboratory Medicine.

Related Links:
Christian Medical College
Horiba
Beckman Coulter
Sysmex Corporation 

 

 

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Clinical Chemistry System
P780

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more